$12.80
0.78% day before yesterday
Nasdaq, Dec 27, 09:50 pm CET
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Day One Biopharmaceuticals Inc Stock price

$12.87
-0.85 6.20% 1M
-0.96 6.94% 6M
-1.73 11.85% YTD
-2.25 14.88% 1Y
-3.10 19.41% 3Y
+11.82 1,125.71% 5Y
+11.82 1,125.71% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.03 0.23%
ISIN
US23954D1090
Symbol
DAWN
Sector
Industry

Key metrics

Market capitalization $1.30b
Enterprise Value $742.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.28
P/S ratio (TTM) P/S ratio 12.73
P/B ratio (TTM) P/B ratio 2.34
Revenue (TTM) Revenue $101.95m
EBIT (operating result TTM) EBIT $-211.46m
Free Cash Flow (TTM) Free Cash Flow $-90.24m
Cash position $558.38m
EPS (TTM) EPS $-1.01
P/E forward negative
P/S forward 11.33
EV/Sales forward 6.48
Short interest 23.34%
Show more

Is Day One Biopharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Day One Biopharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

Buy
90%
Hold
10%

Financial data from Day One Biopharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
102 102
-
100%
- Direct Costs 2.52 2.52
448% 448%
2%
99 99
21,717% 21,717%
98%
- Selling and Administrative Expenses 106 106
54% 54%
104%
- Research and Development Expense 203 203
71% 71%
199%
-210 -210
11% 11%
-206%
- Depreciation and Amortization 1.37 1.37
198% 198%
1%
EBIT (Operating Income) EBIT -211 -211
12% 12%
-207%
Net Profit -84 -84
52% 52%
-83%

In millions USD.

Don't miss a Thing! We will send you all news about Day One Biopharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Day One Biopharmaceuticals Inc Stock News

Positive
Seeking Alpha
4 days ago
Day One Biopharmaceuticals' key asset, tovorafenib, shows promise in treating pediatric low-grade glioma, with ongoing phase 3 trials aiming to expand its use. DAWN's financial health is strong, with $422.8 million in cash and equivalents, ensuring sustainability for over two years despite a net loss excluding licensing revenue. The company's deep cash reserves and promising pipeline, including...
Neutral
GlobeNewsWire
12 days ago
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Con...
Neutral
GlobeNewsWire
about one month ago
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that S...
More Day One Biopharmaceuticals Inc News

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeremy Bender
Employees 155
Founded 2018
Website www.dayonebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today